1. Pyranonaphthoquinone Lactones: A New Class of AKT Selective Kinase Inhibitors Alkylate a Regulatory Loop Cysteine
- Author
-
Cilien Hanna, Clark Eid, Erick Honores, Weiguo Zhang, Leif M. Laakso, Ayako Yamashita, Bernard Dean Johnson, Leonard A. McDonald, Zhong Li, Weidong Ding, Dennis Powell, Jeremy I. Levin, Girija Krishnamurthy, Keiko Tabei, Jaechul Shim, Edward J. Salaski, Shabana Insaf, Lourdes Toral-Barza, Ker Yu, and Tarek S. Mansour
- Subjects
Alkylation ,Stereochemistry ,Antineoplastic Agents ,Lactones ,Structure-Activity Relationship ,Cell Line, Tumor ,Drug Discovery ,medicine ,Humans ,Structure–activity relationship ,Cysteine ,Protein kinase B ,Cell Proliferation ,Pyrans ,chemistry.chemical_classification ,biology ,Kinase ,Stereoisomerism ,Oncogene Protein v-akt ,Enzyme ,chemistry ,Mechanism of action ,Biochemistry ,Enzyme inhibitor ,biology.protein ,Molecular Medicine ,medicine.symptom ,Signal transduction ,Biomarkers ,Naphthoquinones - Abstract
The naturally occurring pyranonaphthoquinone (PNQ) antibiotic lactoquinomycin and related aglycones were found to be selective inhibitors of the serine-threonine kinase AKT. A set of synthetic PNQs were prepared and a minimum active feature set and preliminary SAR were determined. PNQ lactones inhibit the proliferation of human tumor cell lines containing constitutively activated AKT and show expected effects on cellular biomarkers. Biochemical data are presented supporting a proposed bioreductive alkylation mechanism of action.
- Published
- 2009